Diagnocure to market bladder cancer test
This article was originally published in Clinica
Executive Summary
Diagnocure is to commercialise ImmunoCyt, a monoclonal antibody-based diagnostic for bladder cancer, in Canada and Europe. The company estimates the annual market for bladder cancer diagnostics in industrialised countries at more than $300 million.